Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, School of Medicine and Institute on Aging, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
J Neurosci. 2011 Oct 5;31(40):14436-49. doi: 10.1523/JNEUROSCI.3836-11.2011.
Because overactivation of the hypothalamic-pituitary-adrenal (HPA) axis occurs in Alzheimer's disease (AD), dysregulation of stress neuromediators may play a mechanistic role in the pathophysiology of AD. However, the effects of stress on tau phosphorylation are poorly understood, and the relationship between corticosterone and corticotropin-releasing factor (CRF) on both β-amyloid (Aβ) and tau pathology remain unclear. Therefore, we first established a model of chronic stress, which exacerbates Aβ accumulation in Tg2576 mice and then extended this stress paradigm to a tau transgenic mouse model with the P301S mutation (PS19) that displays tau hyperphosphorylation, insoluble tau inclusions and neurodegeneration. We show for the first time that both Tg2576 and PS19 mice demonstrate a heightened HPA stress profile in the unstressed state. In Tg2576 mice, 1 month of restraint/isolation (RI) stress increased Aβ levels, suppressed microglial activation, and worsened spatial and fear memory compared with nonstressed mice. In PS19 mice, RI stress promoted tau hyperphosphorylation, insoluble tau aggregation, neurodegeneration, and fear-memory impairments. These effects were not mimicked by chronic corticosterone administration but were prevented by pre-stress administration of a CRF receptor type 1 (CRF(1)) antagonist. The role for a CRF(1)-dependent mechanism was further supported by the finding that mice overexpressing CRF had increased hyperphosphorylated tau compared with wild-type littermates. Together, these results implicate HPA dysregulation in AD neuropathogenesis and suggest that prolonged stress may increase Aβ and tau hyperphosphorylation. These studies also implicate CRF in AD pathophysiology and suggest that pharmacological manipulation of this neuropeptide may be a potential therapeutic strategy for AD.
由于下丘脑-垂体-肾上腺 (HPA) 轴的过度激活发生在阿尔茨海默病 (AD) 中,应激神经递质的失调可能在 AD 的病理生理学中发挥机制作用。然而,应激对 tau 磷酸化的影响知之甚少,皮质酮和促肾上腺皮质释放因子 (CRF) 对 β-淀粉样蛋白 (Aβ) 和 tau 病理的关系仍不清楚。因此,我们首先建立了慢性应激模型,该模型加剧了 Tg2576 小鼠的 Aβ 积累,然后将该应激范式扩展到具有 P301S 突变 (PS19) 的 tau 转基因小鼠模型,该模型表现出 tau 过度磷酸化、不溶性 tau 包含物和神经退行性变。我们首次表明,Tg2576 和 PS19 小鼠在未应激状态下均表现出增强的 HPA 应激特征。在 Tg2576 小鼠中,1 个月的束缚/隔离 (RI) 应激增加了 Aβ 水平,抑制了小胶质细胞的激活,并使空间和恐惧记忆恶化与非应激小鼠相比。在 PS19 小鼠中,RI 应激促进了 tau 过度磷酸化、不溶性 tau 聚集、神经退行性变和恐惧记忆障碍。这些影响不能通过慢性皮质酮给药来模拟,但可以通过应激前给予 CRF 受体 1 (CRF(1)) 拮抗剂来预防。CRF(1)依赖性机制的作用进一步得到了支持,即与野生型同窝仔相比,过表达 CRF 的小鼠具有更高水平的过度磷酸化 tau。总之,这些结果表明 HPA 失调参与了 AD 的神经发病机制,并表明长时间的应激可能会增加 Aβ 和 tau 过度磷酸化。这些研究还表明 CRF 参与了 AD 的病理生理学,并表明该神经肽的药理学干预可能是 AD 的一种潜在治疗策略。